Celebrex
|
Sibutramine (Meridia® in the USA, Reductil® in Europe), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. It is an anorectic (i.e. it decreases appetite) although it also has antidepressant properties. It was approved by the Food and Drug Administration (FDA) in November 1997[1] for the treatment of obesity.
Sibutramine acts by increasing serotonin and/or adrenaline
levels in the brain. The serotonergic action, in particular, is thought to influence appetite.
Recognized side-effects are dry mouth, headache, constipation and insomnia. It may increase the blood pressure, and is therefore contraindicated in patients with arterial hypertension, or others in whom a rise in blood pressure would be harmful (e.g. patients with angina). Pulmonary hypertension, a problem in some other anorectics, is not a
recognized side-effect.
A study is ongoing into reports of sudden death, heart failure, renal failure and
gastrointestinal problems with Celebrex. Despite petitions, the drug has not been banned by the FDA, but was part of a Senate hearing in 2005.
|
|
Celebrex
News
• Celebrex Shows Benefit In FirstofItsKind Lung Cancer Chemoprevention Trial Me...
Celecoxib, the anti inflammatory medication also known by the trade name Celebrex, has proven to be safe and reduces a specific proliferation measurement of precancerous lesions in the lung, according to a study from The University of Texas M. D. Anderson Cancer Center.
• Celebrex Shows Benefit In FirstofItsKind Lung Cancer Chemoprevention Trial Ne...
Celecoxib, the anti inflammatory medication also known by the trade name Celebrex, has proven to be safe and reduces a specific proliferation measurement of precancerous lesions in the lung, according to a study from The University of Texas M. D. Anderson Cancer Center. This finding demonstrates the significance of COX 2 inhibition toward preventing lung cancer in individuals at higher risk of
• Celebrex, Naproxen Wont Prevent Mental Decline MedicineNet.com
Title: Celebrex, Naproxen Wont Prevent Mental Decline Category: Health News Created: 5/13/2008 2:00:00 AM Last Editorial Review: 5/13/2008
• Celebrex, Naproxen Wont Prevent Mental Decline HealthDay Via Yahoo News
MONDAY, May 12 HealthDay News Contrary to prior studies, a new trial shows that daily use of two popular pain relieving drugs, Celebrex and naproxen, does not prevent cognitive decline in people with a family history of Alzheimers disease.
• Celebrex, Naproxen Wont Prevent Mental Decline HealthCentral.com
Copyright 2008 ScoutNews LLC. All rights reserved. MONDAY, May 12 HealthDay News Contrary to prior studies, a new trial shows that daily use of two popular pain relieving drugs, Celebrex and naproxen, does not prevent cognitive decline in people with a family history of Alzheimers disease.
IMPORTANT NOTICE:
The information provided by FactsOfLaw.com does not
constitute legal advice or any other type of advice and is
provided for educational purposes only without
warranty of any kind. FactsOfLaw.com has not
reviewed the information on this page for accuracy
and is not responsible for any errors, omissions or
inaccuracies. For legal advice you should
consult a licensed attorney. Source: wikipedia.org
|
|
